Peptide cancer vaccines target neoantigens to boost T cells, with promising melanoma and pancreatic trials hinting at a new era in immunotherapy.
Publication|Articles|August 7, 2025
Pharmacy Practice in Focus: Oncology
- August 2025
- Volume 7
- Issue 6
Efficacy and Safety in CPX-351 vs 7+3 in Adults Younger Than 60 Years With AML-MRC or t-AML
CPX-351 shows promise for younger adults with therapy-related AML, offering improved survival post-transplant despite lower initial remission rates.
Advertisement
Advertisement
Treatment with CPX-351 may result in lower initial complete remission rates but better survival outcomes after stem cell transplantation compared with the 7+3 regimen in younger adult patients with therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes.
Related to this article
Peer Reviewed
Creating institution-specific, literacy-friendly chemotherapy education sheets resulted in patient education materials with higher readability scores than similar materials from common chemotherapy education sites.
How oncology pharmacy leaders fight burnout with stay surveys, smarter schedules, and recognition—building resilient teams through loss and turnover.
At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.
Sometimes, a breakthrough matters not only because of what it does for patients today, but because of what it makes possible for tomorrow.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
Pharmacists make a difference in patients’ lives through MTM services.
Advertisement
Advertisement